3248results about "Enzymes" patented technology

To provide a medicine for treating a disease in a mammal.SOLUTION: Provided is a medicine for treating a disease in a mammal, comprising an expression cassette that is a first expression cassette comprising a chimeric gene operably linked to a first expression control element, the chimeric gene comprising a first portion comprising a minigene having an alternatively spliced exon and a second portion encoding a first RNA encoding a protein, the first portion being 5' to the second portion, the second portion lacking an initiation codon or start codon, the alternatively spliced exon comprising a translation initiation regulatory sequence, expression of the protein being controlled by inclusion of the alternatively spliced exon, and the medicine being used in combination with a small molecule splicing modifier that modulates splicing of the alternatively spliced exon.SELECTED DRAWING: Figure 1

The invention discloses lactobacillus kefiranofaciens IMAU12319 and application thereof, belongs to the technical field of microorganisms, and particularly relates to lactobacillus kefiranofaciens IMAU12319 which is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 8, 2024, the preservation address is No. 3, No.1 yard, West Beichen Road, Chaoyang District, Beijing, and the number is CGMCC No.31224. The lactobacillus kefiranofaciens IMAU12319 has the advantages that the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319, and the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319; the invention also relates to an application of the lactobacillus kefiranofaciens IMAU12319 in preparation of a probiotic agent capable of resisting gastrointestinal digestion. The strain disclosed by the invention not only shows good gastrointestinal tract endurance capacity, but also shows relatively strong potential in the aspects of intestinal adhesion, oxidation resistance and bacteriostasis, and has a wide application prospect in leavening agent strains.

A ternary deep eutectic solvent (TDES) system for a biomolecule (for example, chitin) recovery from a biomass (for example, seafood waste), and the method of preparation of ternary deep eutectic solvent (TDES) system, and a process to differentiate / extract / recover biomolecules (such as chitin) from a biomass (such as seafood waste).

The invention belongs to the technical field of microorganisms, and particularly relates to Burkholderia sp.ZL31 with a disease inhibiting and growth promoting function and application of the Burkholderia sp.ZL31, the Burkholderia sp.ZL31 is preserved in the China Center for Type Culture Collection on September 10, 2024, and the preservation number is CCTCC NO: M 20241950. The Burkholderia sp. ZL31 provided by the invention has antagonistic activity on tomato root rot and a variety of plant pathogenic fungi, shows broad-spectrum bacteriostatic activity, and has good application potential in prevention and treatment of tomato root rot and important fungal diseases of a variety of crops. Meanwhile, the strain has very good inorganic phosphorus dissolving capacity, can generate indole-3-acetic acid (IAA), siderophores and cellulase auxin, can promote tomato growth, provides a good biocontrol resource for prevention and treatment of diseases caused by tomato pathogenic fungi, and has very good application value.

The invention relates to a gene modified cell and a method for producing fucosyllactose by using the gene modified cell, in particular to a saccharomyces cerevisiae gene modified cell and application thereof, and belongs to the technical field of biological gene engineering. The present invention provides a genetically modified cell comprising a recombinant nucleic acid sequence encoding a polypeptide having an [alpha]-1, 2-fucosyltransferase polypeptide ([alpha]-1, 2-fucosyltransferase) activity. The alpha-1, 2-fucosyltransferase polypeptide includes, but is not limited to, polypeptides having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical amino acid sequences with the amino acid sequences of SEQ ID NO: 1-25. According to the gene modified cell, the fucosyllactose synthesis capability of an original strain is improved.

The invention belongs to the field of bioengineering, and particularly discloses a glutamate oxidase mutant with improved enzymatic activity. According to the invention, site-specific mutagenesis and saturation mutation are carried out on glutamate oxidase coding genes derived from streptomyces mobaraensis, wherein mutations are C536R, P532R, Q378D, V548E and G236D. After the mutant obtained by the invention is induced and purified, the specific enzyme activity of the optimal glutamate oxidase mutant is 1.69 U / mg and is improved by about 30% compared with that of wild bacteria, which shows that the 378-site amino acid residue has great influence on the catalytic action and stability of the enzyme. In addition, the invention also discloses a construction method of the glutamate oxidase mutant with improved enzymatic activity and application of the glutamate oxidase mutant in production of amino acid derivatives such as alpha-ketoglutaric acid. Therefore, the beneficial mutant provided by the invention can lay a good foundation for industrial fermentation production of alpha-ketoglutaric acid and other products.

The invention relates to the technical field of biological enzymes. The invention provides a biological enzyme gene capable of producing beta-pinene and application of the biological enzyme gene. The biological enzyme gene comprises one or more of TPS1, TPS2, TPS3 and TPS4. The gene disclosed by the invention can be used for preparing a biological enzyme for efficiently catalyzing and producing beta-pinene, and the biological enzyme is used as a catalyst, so that the yield of beta-pinene can be increased, and an efficient, environment-friendly and sustainable production mode is realized. The method can become an important production way of beta-pinene in the future, and has a wide application prospect in industrial production and other fields.

The invention discloses a deoxyartemisinin B synthase and an application of an isoenzyme A0A2U1PPI9 of the deoxyartemisinin B synthase in catalysis of dihydroartemisinin acid for biosynthesis of dihydrodeoxyartemisinin B. The invention further discloses a preparation method of the deoxyartemisinin B synthase. The invention discloses a process for biosynthesizing dihydrodeoxidized artemisinin B from dihydroartemisinin for the first time in a biosynthesis pathway of artemisinin, and bioinformatics analysis and in-vitro activity verification of candidate enzymes show that both the deoxidized artemisinin B synthase and the isoenzyme A0A2U1PPI9 have a new function of catalyzing the biosynthesis of dihydrodeoxidized artemisinin B from dihydroartemisinin, so that the application of the deoxidized artemisinin B synthase and the isoenzyme A0A2U1PPI9 to the biosynthesis of dihydrodeoxidized artemisinin B is developed. Lines of artemisinin biosynthetic pathways are enriched, and a theoretical basis is provided for analysis of terminal biosynthetic pathways of artemisinin and heterologous synthesis of artemisinin compounds.

The invention belongs to the technical field of biology, and particularly relates to a nano antibody-proximity marker enzyme fusion protein and application thereof. Specifically, the present disclosure provides a fusion protein for proximity labeling wherein the fusion protein is operably linked together by (a) a nanobody and (b) a proximity labeling enzyme; optionally, a peptide linker is also included between the nano antibody and the proximity marker enzyme. The nano antibody-proximity marker enzyme fusion protein disclosed by the invention is obtained through in-vitro expression and purification, target protein is targeted by using an antibody, and the nano antibody-proximity marker enzyme fusion protein does not depend on an overexpression system and has compatibility to various cell types, tissues and clinical fixed samples; proteins with post-translational modification and various organelles, such as membraneless organelles, can be targeted; and the positioning accuracy rate reaches 100%.

The invention relates to a method for improving luminous intensity of a plant by introducing an exogenous caffeic acid synthesis pathway. A TAL gene and a P450 gene are introduced into a plant body to obtain a remarkable effect of increasing the expression quantity of caffeic acid. Due to the fact that introduction of the TAL gene and the P450 gene promotes deamination of the L-DOPA, the accumulation amount of the L-DOPA is increased, and then the expression amount of caffeic acid in the plant is effectively increased. Based on the pathway, the synthesis of fluorescein in the plant is increased, so that the luminous intensity of the plant is enhanced.

Provided herein are compositions and methods for improving non-viral insertion of genes into safe harbor loci of cells such as immune cells.

The invention relates to the technical field of biology, in particular to a leucine dehydrogenase mutant and application thereof. According to the leucine dehydrogenase mutant and the application thereof provided by the embodiment of the invention, wild leucine dehydrogenase is subjected to mutation screening to obtain the leucine dehydrogenase mutant with an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2, the catalytic efficiency of asymmetric reductive amination of a prochiral alpha-keto acid compound is improved, and the thermal stability of the leucine dehydrogenase mutant is improved; the synthesis efficiency of the L-amino acid is favorably improved.

The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.

The invention discloses a non-specific peroxygenase mutant and application thereof and a preparation method of 25-hydroxyvitamin D3, and particularly relates to a protein obtained by taking an amino acid sequence as shown in SEQ ID NO.1 as a starting sequence and mutating amino acid residues as shown in the 20th site and / or the 25th site and / or the 57th site. The catalyst has relatively high catalytic activity and stereocatalysis specific selectivity; according to the method, acetone, vitamin D3, hydrogen peroxide and a non-specific peroxygenase mutant are respectively added into a potassium phosphate buffer solution with the pH value of 7.0-8.0 to form a reaction mixed solution, an oxidation reaction is carried out for 10-50 hours at the temperature of 25-35 DEG C, the 25-hydroxyvitamin D3 is generated, the reaction condition is mild, the reaction operation is simple and convenient, the conversion rate is high, the cost is low, the preparation efficiency of the 25-hydroxyvitamin D3 is greatly improved, and the method is suitable for industrial production. Good industrial application prospects are realized.

The invention provides an application of a transporter in improving the yield and / or purity of lactose-N-neotetraose (LNnT), and relates to the technical field of genetic engineering. Transporter proteins of different sources are screened, the transporter protein which aims at LNnT synthesis and can achieve efficient transportation is obtained, and a new biological material is provided for LNnT synthesis. Moreover, the efficient transporter obtained by screening is used for transporting the LNnT to the outside of cells, so that the pressure on the cells caused by overhigh concentration of intracellular products is relieved, the conversion of an intermediate product LNT II to the LNnT is improved to the maximum extent, the yield is improved while byproducts are reduced, the yield of a byproduct lactose-N-neohexaose is also reduced, and the separation and purification of later products are facilitated.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

The imine reductase mutant provided by the invention can catalyze asymmetric reductive amination of ethyl 3-formylhexanoate and (S)-2-aminobutanamide to synthesize brivaracetam, two chiral centers of brivaracetam are constructed in one step, and the problems of poor environmental protection property, low atom utilization rate, long route and the like in the existing industrial synthesis route are solved. Wide application prospects are realized.

The invention relates to the technical field of biology, in particular to a method for efficiently synthesizing L-carnosine in a green mode and application of the L-carnosine. The invention provides the L-carnosine synthetase and the strain, and also provides a method for synthesizing the L-carnosine through an enzyme catalysis method, a green and sustainable biological catalysis process is adopted to improve the synthesis efficiency of the L-carnosine and overcome the problems of low yield, low conversion rate, substrate inhibition and the like in the prior art, and substrate accumulation is optimized through transport protein engineering, so that the yield of the L-carnosine is improved. The production capacity of the product is further improved, and a feasible solution is provided for large-scale industrial production.

The invention discloses a fusion protein of Bst DNA polymerase and ferritin as well as a mutant and application of the fusion protein. The invention firstly provides a Bst DNA polymerase fusion protein obtained by connecting a C end of a monomer ferritin subunit with an N end of a wild type Bst DNA polymerase through a connecting peptide, and large fragments of the wild type Bst DNA polymerase are repeatedly and orderly displayed on the surface of intense pyrococcus ferritin with strong heat resistance, so that the enzyme activity and the heat stability of the fusion protein are improved; the fusion protein is further subjected to single-site and double-site mutation, compared with a wild type Bst DNA polymerase and the fusion protein, the enzymatic activity, specific activity and thermal stability of the obtained mutant are remarkably improved or improved, LAMP specific amplification reaction can still be carried out at the highest temperature of 85 DEG C, and the application prospect is wide. The reaction preciseness is improved, the use cost of the enzyme is reduced, and the method can be applied to a loop-mediated isothermal amplification technology in a more complex scene.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immune disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

The present disclosure provides compositions, kits, and systems comprising engineered bacteria and agricultural biologics, and methods of using the same to treat plants and improve one or more plant beneficial traits, such as plant yield, nutrient uptake, and resistance to abiotic or biological stress. Using the compositions, kits, and systems disclosed herein can further 5 reduce fertilizer usage. The present disclosure also proposes methods of treating plants using the engineered bacteria with agricultural biologics.

The present disclosure is directed to DNA-PK inhibitors having the Formula (I), (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, or tautomer thereof, methods of preparing the foregoing, and compositions thereof, as well as methods of use for the compounds of Formula (I), in combination with a DNA cutting agent.

The invention discloses a high-activity endoglucanase expression optimized strain and application thereof, and belongs to the technical field of gene engineering and enzyme engineering. According to the present invention, PCR amplification and homologous recombination are adopted to carry out strain construction and expression optimization on endoglucanase tCel5A, and screening is performed to obtain the sAOX1-pSUC2-tCel5A strain; an enzymatic property research finds that the recombinant pPICZA-tCel5A has the optimal temperature of 50 DEG C and the optimal reaction pH of 4.5, and has good thermal stability and low pH stability. The enzyme activity determination result shows that the enzyme activity of the sAOX1-pSUC2-tCel5A after expression optimization is 4632.81 U / mg prot, which indicates that the tCel5A after expression optimization can efficiently degrade cellulose, and has a great application prospect in the fields of agriculture, brewing industry and the like.

The invention discloses difunctional glucanase for hydrolyzing agricultural and sideline products and application, and belongs to the technical field of biology. The difunctional glucanase is named as RuCel071, and the amino acid sequence of the difunctional glucanase is as shown in SEQ ID NO. 3. The novel cellulase RuCe071 is developed on the basis of a rumen microorganism metagenome resource mining technology, has the activity of simultaneously hydrolyzing cellulose and xylan, can be used for degrading agricultural and sideline products, reducing accumulation of the agricultural and sideline products and environmental pollution, lowering the treatment cost and improving the degradation efficiency, and has the advantages of being simple in preparation process, low in cost and high in application value. The utilization rate and the economic benefit of agricultural and sideline products are favorably improved.

An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.

The invention relates to a high-efficiency RNA (Ribonucleic Acid) interaction proteome identification method based on a heterozygous proximity marker tool. A brand-new peroxidase APEX2 compound is designed, the peroxidase APEX2 is combined to mRNA, the peroxidase APEX2 can catalyze biotin-phenol under the action of hydrogen peroxide to form biotin-phenoxy free radicals to carry out covalent labeling on proximity proteins, and then technologies such as affinity purification and mass spectrum identification can be utilized to carry out covalent labeling on the proximity proteins. The mRNA interaction protein is efficiently and specifically identified; then mRNA candidate interacting protein is obtained through bioinformatics analysis, finally, the interaction relation between RNA and the candidate protein is verified by combining CLIP, WB and other technologies, and efficient identification of RNA interaction proteome is achieved.

Provided are compounds that may bind a target protein, and result in modification of the target protein. The compounds may further bind a modifier protein. The modifier protein may carry out or enhance the modification of the target protein. The modification may activate or reactivate the target protein. Also provided are methods of using the compounds.

The invention relates to beta-1, 4-glucanase and application thereof, and belongs to the technical field of biology. A novel beta-1, 4-glucanase is screened and identified in Pleurotus tuber-regium, and the beta-1, 4-glucanase has wide substrate specificity, can specifically hydrolyze beta-glucan (such as sodium carboxymethyl cellulose) containing beta-1, 4 glucosidic bonds, and can hydrolyze beta-glucan (such as sodium carboxymethyl cellulose) containing beta-1, 3-1, 4-glucanase) containing beta-1, 3-1, 4-glucanase. The beta-1, 4-glucanase disclosed by the invention can be used for preparing beta-glucan (such as barley beta-glucan and oat beta-glucan) containing beta-1, 3-1, 4 glucosidic bonds, so that the beta-1, 4-glucanase disclosed by the invention has good enzyme activity on the beta-glucan containing the beta-1, 4 glucosidic bonds and the beta-glucan containing the beta-1, 3-1, 4 glucosidic bonds. Besides, the enzyme activity of the beta-1, 4-glucanase disclosed by the invention can be kept at 70% or above under the condition that the pH value is 4.0-7.0, the enzyme activity of the beta-1, 4-glucanase can be kept at 88% or above under the temperature of 40 DEG C, and the beta-1, 4-glucanase has good stability.

The present invention discloses a humanized human-porcine chimeric uricase chimeric mutant. The amino acid sequence of the mutant is shown in SEQ ID NO. 1. The mutant has excellent uric acid level reduction and high homology with human uricase, providing a new option for drug treatment of hyperuricemia.

The disclosure provides conjugates comprising a targeting moiety a lipid nanoparticle (LNP) encapsulating a therapeutic agent (e.g., payload) for delivery to immune cells. The conjugates can be delivered to immune cells ex vivo or formulated in a pharmaceutical composition and can be directly administered to a subject in need of (i.e., via in vivo administration).